NCT03071341View on ClinicalTrials.gov

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions

Mucopolysaccharidosis I

Interventions

DRUG

AGT-181

Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein

Trial Locations (1)

90035-903

HCPA - Hospital das Clinicas de Porto Alegre, Porto Alegre

Sponsors

Lead Sponsor

All Listed Sponsors

lead

ArmaGen, Inc

INDUSTRY